85 results
8-K
EX-99.1
KDNY
Chinook Therapeutics Inc
28 Jul 23
Chinook Therapeutics Announces First Patient Enrolled in Pivotal Phase 3 BEYOND Study of Zigakibart (BION-1301) for Patients with IgA Nephropathy
8:15am
in the BEYOND study, a pivotal phase 3 clinical trial evaluating the safety and efficacy of zigakibart (BION-1301), a potentially disease-modifying anti … , double-blind, placebo-controlled phase 3 clinical trial comparing the safety and efficacy of zigakibart versus placebo in patients with IgAN at risk
DFAN14A
NVS
Novartis AG
10 Jul 23
Additional proxy materials by non-management
4:08pm
and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity
DEFM14A
KDNY
Chinook Therapeutics Inc
10 Jul 23
Proxy related to merger
4:01pm
, the status of our clinical trials and information from our trials that was available to us, including safety data with respect to atrasentan.
On May 15, 2023 … programs and market opportunities, the status of our clinical trials and information from our trials that was available to us, including safety data
PREM14A
KDNY
Chinook Therapeutics Inc
27 Jun 23
Preliminary proxy related to merger
4:02pm
that was available to us, including safety data with respect to atrasentan.
On May 15, 2023, members of our senior management, including Mr. Dobmeier, Eric … and information from our trials that was available to us, including safety data with respect to atrasentan.
On May 16, 2023, Company E provided comments
DEFA14A
lxt8axk14yixckpm9cop
20 Jun 23
Additional proxy soliciting materials
9:05am
8-K
EX-99.1
81deynpn6h9a ecpq
20 Jun 23
CHK-336 was generally well tolerated in healthy volunteers (HV) who received single doses up to 500 mg and multiple doses up to 60 mg for 14 days
9:00am
DEFA14A
aswu6
12 Jun 23
Additional proxy soliciting materials
4:29pm
8-K
EX-99.1
js7al2miirh3
12 Jun 23
Other Events
4:28pm
DFAN14A
39zlf6itzaju1
12 Jun 23
Additional proxy materials by non-management
9:41am
DEFA14A
tsgqrfyv3dtqf0ko y4g
12 Jun 23
Additional proxy soliciting materials
7:05am
8-K
EX-2.1
1fu56f8
12 Jun 23
Chinook Therapeutics Enters into Agreement to be Acquired by Novartis AG
7:00am
8-K
EX-99.1
bo6kax6 48xi7tfmg
9 May 23
Chinook Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Updates
4:03pm
PRE 14A
osmfzt
17 Apr 23
Preliminary proxy
4:51pm
8-K
EX-99.2
l56931n
20 May 22
Regulation FD Disclosure
4:11pm
8-K
EX-99.1
98mnl w2jhxb
20 May 22
Regulation FD Disclosure
4:11pm